Clinical Trials

440 enrolled

Multiple Myeloma, Recurrence

NCT05438043 2026-03-16

A Study of Daratumumab

500 enrolled

Multiple Myeloma

NCT07095452 2026-03-16

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Phase 2/3 Recruiting

660 enrolled

Multiple Myeloma

NCT06768489 2026-03-13

A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma

140 enrolled

Multiple Myeloma

NCT05552222 2026-03-12

MajesTEC-7

1,590 enrolled

Multiple Myeloma

NCT05896228 2026-03-11

Iber-KDd

30 enrolled

Multiple Myeloma

NCT06192979 2026-03-09

Optimize First-line Treatment for AL Amyloidosis With t (11; 14)

Phase NA Recruiting

41 enrolled

Immunoglobulin Light-chain Amyloidosis

NCT06083922 2026-03-06

A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

20 enrolled

Multiple Myeloma

NCT05623020 2026-03-04

MagnetisMM-6

1,116 enrolled

Multiple Myeloma

NCT03937635 2026-03-02

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

288 enrolled

Smoldering Multiple Myeloma

NCT04566328 2026-03-02

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

1,450 enrolled

Multiple Myeloma

NCT05289687 2026-03-02

Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

LymphoidOther hematologic neoplasm

20 enrolled

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06953960 2026-02-23

A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

130 enrolled

Multiple Myeloma, Neoplasms

NCT04973605 2026-02-20

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

246 enrolled

Multiple Myeloma

NCT06892522 2026-02-17

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib

440 enrolled

Multiple Myeloma, Neoplasms

NCT05020236 2026-02-02

MAGNETISMM-5

944 enrolled

Multiple Myeloma

NCT06932562 2026-01-23

A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant

1,000 enrolled

Multiple Myeloma

NCT06974786 2026-01-23

FASTER

100 enrolled

Multiple Myeloma

NCT05137054 2026-01-22

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

317 enrolled

Multiple Myeloma

NCT05898646 2026-01-13

Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial

96 enrolled

Immunoglobulin Light-chain Amyloidosis

NCT05231629 2026-01-09

MASTER-2

300 enrolled

Multiple Myeloma

NCT06679101 2026-01-08

DREAMM-10

520 enrolled

Multiple Myeloma

NCT04991103 2025-12-31

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

40 enrolled

Amyloidosis, Multiple Myeloma, Neoplasm, Residual

NCT05695508 2025-12-24

HD10/DSMMXX

160 enrolled

Multiple Myeloma

NCT06042725 2025-12-24

MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma

100 enrolled

Multiple Myeloma

NCT02343042 2025-12-22

STOMP

300 enrolled

Multiple Myeloma, Recurrence

NCT04068597 2025-12-18

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

LymphoidOther hematologic neoplasmPlasma cell

250 enrolled

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

NCT06827860 2025-12-18

Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse

23 enrolled

Multiple Myeloma, Recurrence

NCT06483139 2025-11-19

Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy

Recruiting

450 enrolled

GenitourinaryPlasma cell

Multiple Myeloma, Acute Kidney Injury

NCT07110844 2025-11-19

Teclistamab-Daratumumab in AL Amyloidosis

25 enrolled

Immunoglobulin Light-chain Amyloidosis

NCT05363111 2025-10-29

Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma

15 enrolled

Multiple Myeloma

NCT07075510 2025-10-29

Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders

30 enrolled

Neoplasms, Plasma Cell

NCT04176718 2025-10-07

Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

43 enrolled

Multiple Myeloma, Recurrence

NCT06785415 2025-09-30

Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma

37 enrolled

Multiple Myeloma

NCT05572229 2025-09-17

IFM2021-01

74 enrolled

Multiple Myeloma

NCT06015724 2025-07-28

DARANIVOVAX

54 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06464991 2025-07-20

FUMANBA-03

240 enrolled

Multiple Myeloma

NCT06867991 2025-07-15

RADIA

200 enrolled

Autoimmune Diseases of the Nervous System, Anti-N-Methyl-D-Aspartate Receptor Encephalitis

NCT05451771 2025-07-08

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

53 enrolled

Phase EARLY_PHASE1 Recruiting

Immunoglobulin Light-chain Amyloidosis, Proteostasis Deficiencies

NCT04139304 2025-06-29

A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

15 enrolled

Lymphoid

Plasmablastic Lymphoma

NCT07021677 2025-06-15

DARA_T_ALL

LymphoidOther hematologic neoplasm

18 enrolled

Neoplasm, Residual, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06409702 2025-06-12

Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection

Phase 4 Recruiting

59 enrolled

Multiple Myeloma

NCT05561387 2025-06-04

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

510 enrolled

Multiple Myeloma

NCT06119685 2025-06-03

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

LymphoidOther hematologic neoplasmPlasma cell

128 enrolled

Lymphoma, Non-Hodgkin, Multiple Myeloma, Hematologic Neoplasms

NCT06622005 2025-04-16

SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

15 enrolled

Multiple Myeloma

NCT04513639 2025-03-20

The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study

Phase 2/3 Recruiting

176 enrolled

Multiple Myeloma

NCT04972942 2025-03-13

ALLO-T-DART

LymphoidOther hematologic neoplasm

30 enrolled

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06697483 2024-11-25

Risk Stratification and MRD-driven Maintenance for MM After ASCT

Phase NA Recruiting

100 enrolled

Multiple Myeloma, Neoplasm, Residual

NCT06187441 2024-08-19

HOVON174MM

599 enrolled

Multiple Myeloma

NCT06505369 2024-07-17

TALTEC

50 enrolled